Elevation Oncology, Inc.

Historical 13F Holders

Symbol: ELEV
CUSIP: 28623U101
All holders as of: Q3 2025
Type: Equity
Class: COM

Reported Value, Excluding Options

Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 28623U101 since 12/18/2024, largest first.

Filer	% of Class	Shares	Form	Filed
Biotechnology Value Fund L P 13G/A	7.0%	4,440,000	13G/A	5/15/2025 Event 3/31/2025
Biotechnology Value Fund L P	3.9%	2,374,712
BVF I GP LLC	3.9%	2,374,712
Biotechnology Value Fund II LP	3.0%	1,826,364
BVF II GP LLC	3.0%	1,826,364
Biotechnology Value Trading Fund OS LP	0.4%	210,388
BVF Partners OS Ltd.	0.4%	210,388
BVF GP Holdings LLC	6.6%	4,201,076
BVF Partners L P/IL	7.0%	4,440,000
BVF Inc/IL	7.0%	4,440,000
Lampert Mark N	7.0%	4,440,000
Under 5%, checked the "5 percent or less" box, or amended by a later filing (8)
Tang Capital Management LLC 13G/A	4.99%	3,115,000	13G/A	8/14/2025 Event 6/30/2025
Tang Capital Management, LLC	4.99%	3,115,000
Kevin Tang	4.99%	3,115,000
Tang Capital Partners, LP	4.99%	3,115,000
Tang Capital Partners International, LP	0%	0
Tang Capital Partners III, Inc	0%	0
Tang Capital Partners IV, Inc	0%	0
Vanguard Group Inc 13G/A	4.4%	2,610,045	13G/A	1/30/2025 Event 12/31/2024
Goldman Sachs Group Inc 13G/A	2.8%	1,683,356	13G/A	2/6/2025 Event 12/31/2024
The Goldman Sachs Group, Inc.	2.8%	1,683,356
Goldman Sachs & Co. LLC	2.8%	1,683,356
BlackRock, Inc. 13G/A	0.6%	369,048	13G/A	7/17/2025 Event 6/30/2025
BML Investment Partners, L.P. 13D/A	0%	0	13D/A	7/28/2025 Event 7/23/2025
Farallon Capital Partners, L.P. 13G/A	0%	0	13G/A	5/7/2025 Event 3/31/2025
Farallon Capital Partners, L.P.	0%	0
Farallon Capital Institutional Partners, L.P.	0%	0
Farallon Capital Institutional Partners II, L.P.	0%	0
Farallon Capital Institutional Partners III, L.P.	0%	0
Four Crossings Institutional Partners V, L.P.	0%	0
Farallon Capital Offshore Investors II, L.P.	0%	0
Farallon Capital F5 Master I, L.P.	0%	0
Farallon Capital (AM) Investors, L.P.	0%	0
Farallon Partners, L.L.C.	0%	0
Farallon Institutional (GP) V, L.L.C.	0%	0
Farallon F5 (GP), L.L.C.	0%	0
Dapice Joshua J.	0%	0
Dreyfuss, Philip D.	0%	0
Dunn Hannah E.	0%	0
Fried, Richard B	0%	0
Gehani, Varun N.	0%	0
Giauque, Nicolas	0%	0
Kim, David T.	0%	0
Linn, Michael G.	0%	0
Luo Patrick (Cheng)	0%	0
Patel, Rajiv A.	0%	0
Roberts, Jr., Thomas G.	0%	0
Saito Edric C.	0%	0
Seybold, William	0%	0
Short Daniel S.	0%	0
Spokes, Andrew J. M.	0%	0
Warren, John R.	0%	0
Wehrly, Mark C.	0%	0
Frazier Life Sciences Public Fund, L.P. 13G/A	0%	0	13G/A	8/14/2025 Event 7/23/2025
Frazier Life Sciences Public Fund, L.P.	0%	0
FHMLSP, L.P.	0%	0
FHMLSP, L.L.C.	0%	0
Frazier Life Sciences Public Overage Fund, L.P.	0%	0
FHMLSP Overage, L.P.	0%	0
FHMLSP Overage, L.L.C.	0%	0
Frazier Life Sciences X, L.P.	0%	0
FHMLS X, L.P.	0%	0
FHMLS X, L.L.C.	0%	0
Frazier Life Sciences XI, L.P.	0%	0
FHMLS XI, L.P.	0%	0
FHMLS XI, L.L.C.	0%	0
James N. Topper	0%	0
Patrick J. Heron	0%	0
Albert Cha	0%	0
James Brush	0%	0
Daniel Estes	0%	0
Logos Global Management LP 13G/A	0%	0	13G/A	2/14/2025 Event 12/31/2024
Logos Global Management LP	0%	0
Logos Global Master Fund LP	0%	0
Logos GP LLC	0%	0
Arsani William	0%	0
Logos Global Management GP LLC	0%	0

13F Holders by Quarter

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2025 Q3	1	2.00 k	$720.00	$0
2025 Q2	68	29.5 M	$10.8 M	$18.4 k
2025 Q1	75	33.8 M	$8.76 M	$17.9 k
2024 Q4	74	40.0 M	$22.5 M	$1.91 k
2024 Q3	72	46.0 M	$27.6 M	$17.0 k
2024 Q2	87	57.3 M	$154 M	$7.56 k
2024 Q1	68	44.2 M	$227 M	$3.59 k
2023 Q4	35	25.9 M	$13.9 M	$0
2023 Q3	43	28.6 M	$18.9 M	$0
2023 Q2	41	31.5 M	$48.8 M	$0
2023 Q1	28	16.2 M	$30.9 M	$0
2022 Q4	29	14.4 M	$13.7 M	$0
2022 Q3	26	14.3 M	$16.1 M	$0
2022 Q2	28	15.4 M	$21.5 M	$0
2022 Q1	32	18.7 M	$47.2 M	$0
2021 Q4	37	18.3 M	$110 M	$0
2021 Q3	23	15.9 M	$123 M	$0
2021 Q2	37	16.2 M	$217 M	$0